Plasma fibronectin during myocardial ischemia-reperfusion: Effects of magnesium, diltiazem, and a novel Mac-1 inhibitor

American Journal of Hematology

Volumn 57, Issue 4, 1998, Pages 309-314

  Serebruany, Victor L ^a   Solomon, Scott R ^b   Herzog, William R ^b   Gurbel, Paul A ^a  

^a UNION MEMORIAL HOSPITAL   (United States)

^b UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

Acute myocardial infarction; Animal model; Diltiazem; Fibronectin; Mac 1 inhibitor; Magnesium; Myocardial stunning

Indexed keywords

CD11B ANTIGEN; DILTIAZEM; FIBRONECTIN; MAGNESIUM SULFATE; N (2,7 DIMETHYL 9 FLUORENYLMETHOXYCARBONYL)LEUCINE;

ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DRUG EFFECT; FEMALE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; STUNNED HEART MUSCLE; SWINE;

ACUTE DISEASE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DILTIAZEM; FEMALE; FIBRONECTINS; HEMODYNAMIC PROCESSES; LEUCINE; MACROPHAGE-1 ANTIGEN; MAGNESIUM; MYOCARDIAL REPERFUSION INJURY; MYOCARDIAL STUNNING; SWINE; TIME FACTORS;

EID: 0031944608     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-8652(199804)57:4<309::AID-AJH7>3.0.CO;2-Y     Document Type: Article

References (33)

1. Mosesson MW, Umfleet RA: The cold-insoluble globulin of human plasma. I. Purification, primary characterization, and relationship to fibrinogen and other cold insoluble fraction components. J Biol Chem 245:5728-5738, 1970.
2. Bastida E, Escolar G, Ordinas A, Sixma JJ: Fibronectin is required for platelet adhesion and for thrombus formation on subendothelium and collagen surfaces. Blood 70:1437-1442, 1987.
3. Zucker MB, Mosesson MW, Broekman MJ, Kaplan KL: Release of platelet fibronectin (cold-insoluble globulin) from alpha granules induced by thrombin or collagen; lack of requirement for plasma fibronectin in ADP-induced platelet aggregation. Blood 54:8-16, 1979.
4. Menard C, Beaulieu AD, Audette M, Corbeil J, Latulippe L: Studies on fibronectin in inflammatory vs. non-inflammatory polymorphonuclear leukocytes of patients with rheumatoid arthritis. II. Synthesis and release of fibronectin in vitro. Clin Exp Immunol 60:347-353, 1985.
5. Woods KL, Fletcher S: Long-term outcome after intravenous magnesium sulphate in suspected acute myocardial infarction: The second Liecester Intravenous Magnesium Intervention Trial (LIMIT-2). Lancet 343:816-819, 1994.
6. ISIS-4: A randomized factorial trial assessing early oral captopril, oral mononitrate and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction. ISIS collaborative group. Lancet 345:669-685, 1995.
7. Yusuf S: An overview of the clinical trials of agents (other than beta-blockers), that potentially limit myocardial infarct size. J Cardiovasc Pharm 12(Suppl 1):S48-55, 1988.
8. Roberts R: Review of calcium antagonists trials in acute myocardial infarction. Clin Cardiol 12(Suppl III):4-47, 1989.
9. Kimura T, Yasue H, Sakaino N, Rokutanda M, Jougasaki M, Araki H: Effects of magnesium on the tone of isolated human coronary arteries. Circulation 79:1118-1124, 1989.
10. Cho PW, Gillinov AM, Zehr KJ, Burch RM, Winkelstein JA, Cameron DE: Neutrophil activation mediates protamine-induced pulmonary hypertension. J Surg Res 54:486-493, 1993.
11. Bator JM, Weitzberg M, Burch RM: NPC 15669, prevents neutrophil adherence to endothelium and inhibits CD 11b/CD18 upregulation. Immunopharmacology 23:139-149, 1992.
12. Tanaka M, Brooks SE, Richard VJ, FitzHarris GP, Stoler RC, Jennings RB, Arfors K-E, Reimer KA: Effect of anti-CD 18 antibody on myocardial neutrophil accumulation and infarct size after ischemia and reperfusion in dogs. Circulation 87:526-535, 1993.
13. Herzog WR, Gurbel PA, Vogel RA, Schlossberg ML, Schneider AI, Serebruany VL: Effects of a novel leumedin NPC 15669 on myocardial stunning and preconditioned infarction size in swine. J Thromb Thrombolys 1:163-170, 1995.
14. Bolli R: Mechanism of myocardial "stunning." Circulation 82:723-738, 1990.
15. Braunwald E, Kloner RA: Myocardial reperfusion: A double edged sword? J Clin Invest 76:1713-1719, 1985.
16. Bolli R: Myocardial stunning in man. Circulation 86:1671-1691, 1992.
17. Braunwald E, Kloner RA: The stunned myocardium: Prolonged, post ischemic ventricular dysfunction. Circulation 66:1146-1149, 1992.
18. Hearse DJ, Bolli R: Reperfusion induced injury: Manifestations, mechanisms, and clinical relevance. Trends Cardiovasc Med 1:233-240, 1991.
19. Lucchesi BR: Myocardial ischemia, reperfusion and free radical injury. Am J Cardiol 65:141-231, 1990.
20. Opie LH: Reperfusion injury and its pharmacologic modification. Circulation 80:1049-1062, 1989.
21. Herzog WR, Schlossberg ML, MacMurdy KS, Edenbaum LR, Gerber MG, Vogel RA, Serebruany VL: Timing of magnesium therapy affects experimental infarct size. Circulation 92:2622-2626, 1995.
22. Atar D, Serebruany V, Poulton J, Godard J, Schneider A, Herzog WH: Effects of magnesium supplementation in a porcine model of myocardial ischemia and reperfusion. J Cardiovasc Pharm 24:603-611, 1994.
23. Dyck RF, Orchard RC, Senger DL: The response of plasma fibronectin to acute myocardial infarction in humans. Clin Invest Med 13:107-110, 1990.
24. Gresham HD, Goodwin JL, Allen PM, Anderson DC, Brown EJ: A novel member of the integrin receptor family mediates Arg-Gly-Asp-stimulated neutrophil phagocytosis. J Cell Biol 108:1935-1943, 1989.
25. Norton PA, Hynes RO: Characterization of HeLa nuclear factors which interact with a conditionally processed rat fibronectin premRNA. Biochem Biophys Res Commun 195:215-221, 1993.
26. Wang L, Asem EK, McLaughlin GL: Calcium enhances Acanthamoeba polyphaga binding to extracellular matrix proteins. Invest Ophthalmol Vis Sci 35:2421-2426, 1994.
27. Iwata M, Nakano E: Enhancement of spicule formation and calcium uptake by monoclonal antibodies to fibronectin-binding acid polysaccharide in cultured sea urchin embryonic cells. Cell Differ 17:57-62, 1985.
28. Corbi AL, Kishimoto TK, Miller LJ, Springer TA: The human leukocyte adhesion glycoprotein Mac-1 (complement receptor type 3, CD11b) alpha subunit. Cloning, primary structure, and relation to the integrins, von Willebrand factor and factor B. J Biol Chem 263:12403-12411, 1988.
29. Hartfield PJ, Greaves MW, Camp RD: Beta 1 integrin-mediated T cell adhesion is regulated by calcium ionophores and endoplasmic reticulum Ca(2+)-ATPase inhibitors. Biochem Biophys Res Commun 196: 1183-1187, 1993.
30. Fedor JL, McIntosh DM, Rembert JC, Greenfield JC: Coronary and transmural myocardial blood flow responses in awake domestic pigs. Am J Physiol 235:H435-444, 1978.
31. Serebruany VL, Herzog WR, Gurbel PA, Schlossberg ML, Scott HJ, Vogel RA: NPC 15669, an antiinflammatory leucine derivate, reduces in vitro platelet aggregability in both swine and human plasma. J Thromb Thrombolys 1:171-178, 1995.
32. Softeland E, Framstad T, Thorsen T, Holmsen H: Porcine platelets in vitro and in vivo studies: Relevance to human thrombosis research. Eur J Haematol 49:161-173, 1992.
33. Yao SK, Ober JC, Gonenne A, Clubb FJ Jr, Krishnaswami A, Ferguson JJ, Anderson HV, Gorecki M, Buja LM, Willerson JT: Active oxygen species play a role in mediating platelet aggregation and cyclic flow variations in severely stenosed and endothelium-injured coronary arteries. Circ Res 73:952-967, 1993.